Search results for: Generics
Filter search results
Prices, Competition and Regulation in Pharmaceuticals: A Cross-National Comparison
1 June 2000
…basket including generics and appropriate weighting, shows that crossnational price differences are less than suggested by previous studies. The indexes with UK consumption weights show the UK either lowest based…
The Dynamics of Drug Shortages
9 January 2024
…and Capsules are the most common drug presentations to experience drug shortages. References Elzawawy, A., 2015. The Shortage of Essential Cancer Drugs and Generics in the United States of America….
The Impact of Biosimilars on Markets
24 May 2010
…‘biosimilars’ is still difficult, both for individual products and for the market as a whole. The experience with generics may be a guide, but probably not a highly reliable one. In…
Projecting Expenditure on Medicines in the NHS
4 January 2013
…of generics. Most projections of medicines spending are rooted in the past and are “top-down”, macro-type approaches. These models cannot anticipate changes in the mix of medicines available. In this…
OHE at the 2019 International Health Economics Association (iHEA) World Congress
5 July 2019
…Koonal Shah, Mikel Berdud, and Olga Rozanova will be attending to present work from some of OHE’s projects. Understanding Shortages in the UK Generics Market In this session, Adrian…
Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement
17 February 2015
…undermines the relationship between drug prices and per capita income Generics are priced roughly 30% lower than originators on average, but the variance is large, and this could reflect poorer…
Pricing Variations Within and Across Countries: Gauging Efficiency
25 February 2014
…prices in MLICs are associated with income inequalities within the countries. Although prices of generics are about 30% lower than originators on average, the variance is large. Uncertainty about the…
OHE Develops New, Bottom-Up Model for Forecasting UK Medicines Expenditure
3 April 2013
…the market or the appearance of generics. Most projections of medicines spending are rooted in the past and are “top-down”, macro-based approaches. Such models are based on econometric analyses of…
Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
4 January 2024
…/use to extend the data protection period of another product in order to ensure predictability for competitor products, including generics and biosimilars. Eligibility criteria linked to obligations for supply of…